基因编辑治疗的全球市场

本报告调查了全球基因编辑治疗市场，并提供了市场概况、市场影响因素和市场机会分析、新兴技术和技术发展趋势、管道分析、市场规模趋势和预测、各个细分市场和地区。 、主要企业简介等等。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场概况

第二章 市场概况

• 基因组编辑工具的类型
• Meganucleases
• 锌指核酸酶
• 转录激活剂样效应核酸酶
• CRISPR/CRISPR相关蛋白9
• 基因编辑疗法

第三章市场动态

• 市场动态简介
• 市场驱动因素
• 慢性病流行
• 罕见遗传疾病增加
• 精准医疗
• 加强策略性倡议
• 市场限制因素
• 严格的法规结构和漫长的核准流程
• 治疗费用上涨
• 不利事件和长期监测
• 缺乏熟练的工程师
• 脱靶效应
• 市场挑战
• 专利纠纷
• 政府政策法规
• 道德问题
• 市场机会

第四章新兴科技与发展

• 碱基编辑
• 主要编辑
• Cas-Clover 和 Cas-FOKl
• CRISPR 干扰和 CRISPR 激活
• RNA编辑
• 人工智慧在基因组编辑的应用

第五章 管道分析

• 概述
• 临床试验分析：依技术分类
• 临床试验分析：依疾病分类
• 管道药物名称

第六章 专利分析

第七章市场分析

• Casgevy
• 市场概况
• 市场分析
• 区域市场
• 北美洲
• 欧洲
• 新兴市场

第八章 竞争讯息

• 策略倡议
• 竞争格局

第九章基因编辑疗法市场的永续性：环境、社会与管治(ESG) 视角

• 基因编辑公司的 ESG 实践
• BCC 的结论

第10章附录

• 调查方法
• 来源
• 缩写词
• 公司简介
• ALLOGENE THERAPEUTICS
• BEAM THERAPEUTICS
• CARIBOU BIOSCIENCES INC.
• CRISPR THERAPEUTICS
• EDITAS MEDICINE
• INTELLIA THERAPEUTICS INC.
• PRECISION BIOSCIENCES
• SANGAMO THERAPEUTICS
• VERTEX PHARMACEUTICALS INC.
• VERVE THERAPEUTICS INC.
• VOR BIO

The report provides an overview of current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also include company profiles of key players, featuring detailed information regarding each company’s business segments, financials, product portfolios and recent developments. 

Report Scope:

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029. Also included are company profiles of key players, featuring detailed information regarding each company's business segments, financials, product portfolios and recent developments.

Report Includes:

• 15 data tables and 42 additional tables
• An analysis of the current and future global markets for gene editing therapeutics
• Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region
• Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies
• Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and consumer attitudes
• Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding
• Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Introduction
• Genome-Editing Tool Types
• Meganucleases
• Zinc Finger Nucleases
• Transcription Activator-like Effector Nucleases
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
• Gene editing Therapeutics

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Increasing Prevalence of Chronic Disease
• Increasing Prevalence of Rare Genetic Disorders
• Precision Medicine
• Increasing Strategic Initiatives
• Market Restraints
• Stringent Regulatory Frameworks and Time-Consuming Approval Processes
• High Cost of Treatment
• Adverse Events and Long-Term Monitoring
• Lack of Skilled Workforce
• Off-Target Impact
• Market Challenges
• Patent Disputes
• Governmental Policies and Regulations
• Ethical Issues
• Market Opportunities

Chapter 4 Emerging Technologies and Developments

• Introduction
• Base Editing
• Prime Editing
• Cas-Clover and Cas-FOKl
• CRISPR Interference and CRISPR Activation
• RNA Editing
• Artificial Intelligence in Genome Editing

Chapter 5 Pipeline Analysis

• Overview
• Clinical Trial Analysis Based on Technology
• Clinical Trial Analysis Based on Diseases
• Designations for Pipeline Drugs

Chapter 6 Patent Analysis

Chapter 7 Market Analysis

• Introduction
• Casgevy
• Market Overview
• Market Analysis
• Market by Region
• North America
• Europe
• Emerging Markets

Chapter 8 Competitive Intelligence

• Strategic Initiatives
• Competitive Landscape

Chapter 9 Sustainability in the Gene Editing Therapeutics Market: Environmental, Social and Governance (ESG) Perspectives

• Introduction
• ESG Practices in the Gene Editing Companies
• Concluding Remarks from BCC Research

Chapter 10 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• ALLOGENE THERAPEUTICS
• BEAM THERAPEUTICS
• CARIBOU BIOSCIENCES INC.
• CRISPR THERAPEUTICS
• EDITAS MEDICINE
• INTELLIA THERAPEUTICS INC.
• PRECISION BIOSCIENCES
• SANGAMO THERAPEUTICS
• VERTEX PHARMACEUTICALS INC.
• VERVE THERAPEUTICS INC.
• VOR BIO

List of Tables

• Summary Table : Global Market for Gene Editing Therapeutics, Through 2029
• Table 1 : Comparison of Genome-Editing Tools
• Table 2 : U.S. Adults Age 50 Years and Older with Multiple Chronic Conditions, 2020-2050
• Table 3 : Global Cases and Deaths Due to Various Cancers, 2022
• Table 4 : Gene Editing Index Ratings, 2020
• Table 5 : Rating Guide
• Table 6 : Comparison of Cas9-derived Proteins with Regular SpCas9
• Table 7 : Gene Editing Therapeutic Trials in Phase I, Till May 2024
• Table 8 : Gene Editing Therapeutic Trials in Phase I/II, II and III, Till May 2024
• Table 9 : Casgevy Label Expansion Studies, Till May 2024
• Table 10 : Examples of Some Pipeline Drugs and Their Designations, as of May 2024
• Table 11 : Patents on CRISPR Therapeutics, Published in 2021
• Table 12 : Patents on CRISPR Therapeutics, Published in 2022
• Table 13 : Patents on CRISPR Therapeutics, Published in 2023
• Table 14 : Global Market for Gene Editing Therapeutics, Through 2029
• Table 15 : Global Market for Gene Editing Therapeutics, by Region, Through 2029
• Table 16 : Strategic Initiatives in the Gene Editing Therapeutics Market, 2020-2024
• Table 17 : Venture Funding for Startups, 2023
• Table 18 : ESG Initiatives/Practices by Various Gene Editing Companies, 2023
• Table 19 : ESG Rankings for Companies in the Gene Editing Therapeutics Market, 2023
• Table 20 : Report Information Sources
• Table 21 : Glossary of Terms Used in This Report
• Table 22 : Allogene Therapeutics: Company Snapshot
• Table 23 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
• Table 24 : Allogene Therapeutics: News/Key Developments, 2020-2024
• Table 25 : Beam Therapeutics: Company Snapshot
• Table 26 : Beam Therapeutics: Financial Performance, FY 2022 and 2023
• Table 27 : Beam Therapeutics: News/Key Developments, 2021-2023
• Table 28 : Caribou Biosciences Inc.: Company Snapshot
• Table 29 : Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
• Table 30 : Caribou Biosciences Inc.: News/Key Developments, 2021-2024
• Table 31 : CRISPR Therapeutics: Company Snapshot
• Table 32 : CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
• Table 33 : CRISPR Therapeutics: Product Portfolio
• Table 34 : CRISPR Therapeutics: News/Key Developments, 2021-2024
• Table 35 : Editas Medicine: Company Snapshot
• Table 36 : Editas Medicine: Financial Performance, FY 2022 and 2023
• Table 37 : Editas Medicine: News/Key Developments, 2022-2024
• Table 38 : Intellia Therapeutics Inc.: Company Snapshot
• Table 39 : Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
• Table 40 : Intellia Therapeutics Inc.: News/Key Developments, 2021-2024
• Table 41 : Precision Biosciences: Company Snapshot
• Table 42 : Precision Biosciences: Financial Performance, FY 2022 and 2023
• Table 43 : Precision Biosciences: News/Key Developments, 2020-2024
• Table 44 : Sangamo Therapeutics: Company Snapshot
• Table 45 : Sangamo Therapeutics: Financial Performance, FY 2022 and 2023
• Table 46 : Sangamo Therapeutics: News/Key Developments, 2024
• Table 47 : Vertex Pharmaceuticals Inc.: Company Snapshot
• Table 48 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 49 : Vertex Pharmaceuticals Inc.: Product Portfolio
• Table 50 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
• Table 51 : Verve Therapeutics Inc.: Company Snapshot
• Table 52 : Verve Therapeutics Inc.: Financial Performance, FY 2022 and 2023
• Table 53 : Verve Therapeutics Inc.: News/Key Developments, 2019-2024
• Table 54 : Vor Bio: Company Snapshot
• Table 55 : Vor Bio: Financial Performance, FY 2022 and 2023
• Table 56 : Vor Bio: News/Key Developments, 2020-2024

List of Figures

• Summary Figure : Global Market for Gene Editing Therapeutics, 2021-2029
• Figure 1 : Genome-Editing Outcomes
• Figure 2 : Endonucleases Used in Gene Editing Technologies
• Figure 3 : Advances in Therapeutic Strategies to Treat Life-Threatening Diseases
• Figure 4 : CRISPR/Cas9 Therapeutics Timeline, Since 1987-Present
• Figure 5 : CRISPR/Cas9 Therapeutics Delivery Platform
• Figure 6 : Delivery Method
• Figure 7 : Market Dynamics of Gene Editing Therapeutics Market
• Figure 8 : Genetic Disorders
• Figure 9 : Emerging Technologies in the Genome-Editing Therapeutics Market
• Figure 10 : Emerging Therapeutics Applications for RNA Editing by Cas Enzymes
• Figure 11 : Articles on Gene Editing Therapeutics in PubMed, 2004-2024
• Figure 12 : Share of Clinical Trials on the Genome-Editing Market, by Technology, Through May 2024
• Figure 13 : Genome-Editing Clinical Trials, by Diseases
• Figure 14 : Genome-Editing Clinical Trials, by Trial Phase
• Figure 15 : Genome-Editing Clinical Trials, by Trial Status
• Figure 16 : Patents Documented, by Top Owners, 2021-2024
• Figure 17 : Patents Documented, by Type, 2021-2024
• Figure 18 : Patents Documented, by Type, 2021-2024
• Figure 19 : Common Strategies Proposed for the Therapeutic Intervention for B-thalassemia and Sickle Cell Disease
• Figure 20 : Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 21 : Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 22 : Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023